GCM
USNA icon

Gladius Capital Management’s Usana Health Sciences USNA Stock Holding History

Gladius Capital Management’s Portfolio USNA Stock Details USNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,007
Closed -$146K – 503
2022
Q2 		$146K Buy
2,007
+1,102
+122% +$82.1K 0.01% 169
2022
Q1 		$72K Buy
905
+152
+20% +$13.7K 0.01% 252
2021
Q4 		$77K Buy
+753
New +$75.1K 0.01% 278

Other funds holding USNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Pzena Investment Management
Pzena Investment Management New York $30.8B AUM 11.29% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Gladius Capital Management's USNA Position: Q3 2022 in Review

Gladius Capital Management sold out of Usana Health Sciences (USNA) in Q3 2022, closing a stake of 2,007 shares — an estimated $146K sold.

Gladius Capital Management first reported a position in USNA in Q4 2021 and held it in 3 quarters. The position peaked at $146K in Q2 2022. 172 funds tracked by Wall St. Rank hold USNA as of Q3 2022.

  • Gladius Capital Management reported no remaining Usana Health Sciences position as of Q3 2022 after selling out during the quarter.
  • Gladius Capital Management sold 2,007 Usana Health Sciences shares in Q3 2022, an estimated $146K.
  • Gladius Capital Management first reported a position in Usana Health Sciences in Q4 2021 and held it in 3 quarters.
  • Gladius Capital Management's Usana Health Sciences position peaked at $146K in Q2 2022.
  • 172 funds tracked by Wall St. Rank held Usana Health Sciences as of Q3 2022.

Based on Gladius Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.